Skip to main content

Advertisement

Table 4 BNCT clinical trials using epithermal neutron beams for patients with recurrent or untreated unresectable head and neck cancer

From: Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

Medical institution Neutron source Treatment dates Tumor type & No. of patients Boron compounda Clinical outcome Ref.
Osaka University, Oral & Maxillofacial Surgery II, Osaka, Japan KURR (Kyoto University Research Reactor, Osaka, Japan) or JRR-4, Japan Atomic Energy Agency, Tokai Research Establishment, Ibaraki, Japan 2001-2007 26 rH&N BSH 5 g & BPA 250 mg/kg in 1 h Or BPA 250–500 mg/kg in 1–2 h MeST: 7.9 mos. post BNCT [5, 6], This Paper
      PR: 39%  
      CR: 46%  
      2 & 4 y OS: 37%,  
      6 y OS: 32%  
Osaka Medical College, Osaka, Japan KURR 2005-2008 6 rOC BPA 500 mg/kg (200 mg/kg h × 2 h; 100 mg/kg h × ~1 h during irradiation) PR: 67% [113115]
      CR: 17%  
Kyoto University Research Reactor Institute (KURRI), Kyoto University, Osaka, Japan KURR 2001-2007 49 rH&N BSH & BPA 250–500 mg/kg PR: 29%, CR: 28% [116, 117] This paper
    13 urH&N    
      MeST: 10.1 mos. (n = 53)  
      2 y OS: 24%  
Kawasaki Medical School, Kurashiki, Japan KURR or JRR-4 2003-2007 10 rSqCC BPA 500 mg/kg (200 mg/kg h × 2 h; 100 mg/kg h × ~1 h during irradiation) PR: 35% [4, 118, 119]
    7 rnSqCC    
    3 nSqCC   CR: 55%  
      2 y OS: 32.3%  
  JRR-4 2005-2008 10 H&N MM BPA 500 mg/kg PR: 50% [120]
      CR: 40%  
Helsinki University Central Hospital, Helsinki, Finland FiR-1, VTT Technical Research Centre, Espoo, Finland 2003-2008 24 rSqCC BPA 400 mg/kg in 2 h PR: 31% [7]
      CR: 45%  
    6 rnSqCC    
      MeST: 13 mos. post BNCT  
      2 y OS: 30%  
   2010 1 ur PDC BPA 400 mg/kg in 2 h CR: 1/1 [121]
     BNCT + Chemo-RT (IMRT + SRT) with cetuximab and cisplatin   
Taipei Veterans General Hospital, Taipei, Taiwan THOR, National Tsing Hua University, Hsinchu, Taiwan 2010-2011 10 rH&N BPA ~450 mg/kg (180 mg/kg h × 2 h; 90 mg/kg h × ~1 h during irradiation) PR: 40% [122, 123]
      CR: 30%  
  1. aThis column also indicates treatment in cases of multi-modality treatment.
  2. Abbreviations: rH&N recurrent head and neck cancer, rOC recurrent oral cancer, ur unresectable, rSqCC recurrent squamous cell carcinoma, rnSqCC recurrent non-squamous cell carcinoma, nSCC non-squamous cell carcinoma (naïve), H&N MM mucosal melanoma of the head and neck, PDC poorly differentiated carcinoma, XRT external beam radiation therapy (photons), IMRT intensity modulated radiation therapy, SRT stereotactic radiation therapy, PR partial response, CR complete response, 2 y OS 2-year overall survival, MeST median survival time, given in months.